Surprising Heart Results from This Huge Melatonin Study

Unlike sedatives (e.g., antihistamines or benzodiazepines) that acutely depress the central nervous system, melatonin provides a temporal cue. To phase-advance the clock, melatonin should be present when the endogenous melatonin onset (dim light melatonin onset) hasn’t occurred yet, which is typically 2–3 hours before habitual bedtime. Taking it later provides a weaker phase shift and may even delay sleep if taken after the onset. Proper timing is especially critical for people with circadian rhythm disorders or mild insomnia. The speaker stresses this distinction because the lay public often misuses melatonin as a knock-out pill, which reduces its effectiveness and increases the risk of next-day sedation.

Brad Stanfield calculates that to avoid flooding the body with melatonin levels far above natural, one needs to keep the absorbed dose near the endogenous production. He chooses 300 micrograms as a precise, safe middle ground. This approach is backed by the fact that many studies showing sleep benefits used doses of 0.1–0.3 mg. The pervasive 5 mg and 10 mg pills on store shelves are marketing artifacts, not science-based. Additionally, a 2023 study revealed that actual melatonin content in gummies ranged from 74% to 347% of the label, with one product having zero melatonin. Therefore, he stresses finding a manufacturer that supplies third-party certificates of analysis, so you know exactly what you are getting. He acknowledges that even this low dose is based on extrapolation; long-term RCTs using physiological doses are needed.

The 2023 study exposed a near-complete lack of regulation in the melatonin gummy market. Inconsistent dosing can render low-dose strategies impossible (if the pill is way over target) or ineffective (if near zero). The speaker implies that gummies are particularly prone to variation and that the safest route is to find a manufacturer that subjects its products to independent lab testing and makes those results accessible. This practice mirrors recommendations for other dietary supplements where quality control is the consumer’s responsibility. He doesn’t endorse a specific brand but frames the COA as a non-negotiable quality checkpoint.

The researchers used prescription records to define the melatonin group, so anyone who obtained melatonin over the counter (as is the norm in the US) was classified as a non-user. This contaminates the control group and makes it impossible to attribute any outcome differences to melatonin. Furthermore, the study was observational, not randomized, so it can only report associations, not causation. A likely confounder is that people with more severe insomnia are more likely to seek a prescription, and insomnia itself is a well-established risk factor for heart disease through inflammation and other pathways. Thus, the supposed melatonin–heart failure link is easily explained by the underlying disease rather than the supplement. The fact that this was an unreviewed abstract amplified the noise. Methodologically rigorous evidence—randomized controlled trials—points in the opposite direction.

The meta-analysis pooled results from 63 trials involving over 3,000 participants. It found significant reductions in waist circumference, systolic and diastolic blood pressure, fasting blood glucose, LDL cholesterol, and total cholesterol. Melatonin also significantly lowered several markers of inflammation (like C-reactive protein and interleukin-6) and oxidative stress, while boosting total antioxidant capacity. The effect sizes were modest—not dramatic—but cumulatively they point strongly toward cardiovascular benefit. Importantly, these were randomized comparisons, so confounding by indication is minimized. The caveat is that most trials lasted only weeks, and the longest just over a year, so it doesn’t settle the question of long-term safety. Still, when viewed through the lens of controlled evidence, the data trend positively.

The body naturally produces 10–80 micrograms of melatonin per night. Oral bioavailability of typical supplements is about 15%. Thus, a 5 mg pill (5,000 mcg) results in roughly 750 mcg absorbed—at least 10 times the upper physiological amount. Stanfield’s dose of 300 mcg (0.3 mg) yields about 45 mcg absorbed, comfortably within the natural range. His choice is motivated by the desire to mimic biology and avoid unrecognized long-term risks of massive overdosing. This insight, combined with the earlier finding that supplement labels can be wildly inaccurate (one product had 347% of the claimed dose), makes precise, low-dose sourcing critical.

Melatonin is produced outside the brain in sites like the gastrointestinal tract and skin, where it acts locally. As an antioxidant, it directly scavenges free radicals and upregulates endogenous antioxidant enzymes. It also dampens inflammation by inhibiting pro-inflammatory cytokines and signaling pathways. Additionally, it enhances endothelial function, promoting better blood vessel dilation and health—a key factor in preventing atherosclerosis. These properties plausibly explain the improvements in blood pressure, lipids, and inflammatory markers seen in the 2025 meta-analysis. Together, they build a compelling biological case that melatonin supports, rather than harms, cardiovascular health.